Replies to post #212974 on Bioelectronics Corp (BIEL)

[Biotech_Tradez]

They are not uplisting nowhere near close to qualifying.

Neither ENDV nor BIEL have reimbursement nor value added contracts in place except for BIEL in the UK.

Therefore, neither company will generate any meaningful revenue. To get reimbursement in the US or value-based contracts very large clinical trials need to be conducted to show the benefit and how much it saves.